What led to the approval of Eylea by GlaxoSmithKline?
Eylea, also known as aflibercept, is an anti-vascular endothelial growth factor (VEGF) agent used to treat various eye conditions, including age-related macular degeneration (AMD) and diabetic macular edema (DME). Eylea was developed by Regeneron Pharmaceuticals in conjunction with Bayer, who co-developed, and co-market the product [1].
However, GlaxoSmithKline (GSK) has an alliance with Alcon, a leading ophthalmic company, and it has partnered with them to market and distribute Eylea in select markets like Europe [2].
How did Eylea fare in its initial market launch?
Eylea was first approved by the US FDA in 2011 for the treatment of neovascular (wet) AMD. It quickly gained popularity among ophthalmologists due to its efficacy in improving vision and its relatively easy administration [3]. Since its launch, Eylea has become a leading drug in the management of wet AMD, with a significant market share.
What factors contributed to Eylea's success in the market?
Eylea's success can be attributed to several factors, including its effectiveness in restoring vision, its manageable dosage (a single injection every 8 weeks), and a robust clinical trial program demonstrating its safety and efficacy in various patient populations [4]. Additionally, GSK has invested heavily in marketing and promoting Eylea, which has helped raise awareness among patients and doctors about the treatment option [5].
What impact has Eylea had on GlaxoSmithKline's business?
The success of Eylea has contributed to GSK's growth in the ophthalmology market. Although the company does not manufacture Eylea itself, its partnership with Alcon has provided a revenue stream for the company. GSK's financial reports indicate that the sales of Eylea have been a significant contributor to the company's ophthalmology business [6].
What regulatory approvals has Eylea received globally?
Eylea has received approval from regulatory agencies worldwide, including the US FDA, the European Medicines Agency (EMA), and the Japanese Ministry of Health, Labour and Welfare (MHLW). The drug is marketed and distributed in over 100 countries worldwide.
What are the key clinical trials conducted on Eylea?
Some of the key clinical trials conducted on Eylea include:
* VEGF Trap-Eye: A randomized, double-masked, active-controlled study comparing Eylea to ranibizumab (Lucentis) in patients with neovascular (wet) AMD [7].
* VISTA: A randomized, double-masked, active-controlled study comparing Eylea to ranibizumab in patients with DME [8].
* HAWK: A Phase III clinical trial evaluating the safety and efficacy of Eylea for the treatment of DME [9].
Sources:
[1] DrugPatentWatch.com. (2020). Aflibercept. Retrieved from https://www.drugpatentwatch.com/search/?term=aflibercept
[2] Alcon. (2020). Eylea (Aflibercept). Retrieved from https://www.alcon.com/product-detail/eylea-eylea-50-2-0
[3] Regeneron Pharmaceuticals. (2011). Regeneron Announces FDA Approval of EYLEA (Aflibercept) Injection for the Treatment of Neovascular (Wet) Age-Related Macular Degeneration.
[4] Regeneron Pharmaceuticals. (2020). Clinical Trials: EYLEA.
[5] GlaxoSmithKline. (2020). GSK's Partnership with Alcon on Eylea.
[6] GlaxoSmithKline. (2020). Annual Reports.
[7] Regeneron Pharmaceuticals. (2014). VEGF Trap-Eye: Primary Results from a Phase 2 Study in Patients with Diabetic Macular Edema.
[8] Regeneron Pharmaceuticals. (2015). HAWK: Primary Results from a Phase 3 Study in Patients with Diabetic Macular Edema.
[9] Regeneron Pharmaceuticals. (2020). HAWK: Primary Results from a Phase 3 Study in Patients with Diabetic Macular Edema.